SWOG clinical trial number
SWOG-9332
Phase III trial of Adriamycin Versus Taxol Versus Taxol Plus Adriamycin Plus G-CSF in Metastatic Breast Cancer, Intergroup
Closed
Published
Abbreviated Title
Phase III trial of Adriamycin Versus Taxol Versus Taxol Plus Adriamycin Plus G-CSF in Metastatic Breast Cancer, Intergroup
Activated
01/01/1994
Closed
09/29/1995
Research committees
Breast Cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase